Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with T
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2022 | TERT-BUTYL ALCOHOL | INTRAVENOUS | INJECTION | 0.03 %w/v | Deletion | ||
| Q3 2022 | TERT-BUTYL ALCOHOL | SUBCUTANEOUS | INJECTION | 0.03 %w/v | Deletion | ||
| Q3 2022 | TITANIUM DIOXIDE | ORAL | TABLET, COATED PARTICLES | 15.00 mg | 120mg | Deletion | |
| Q3 2022 | TRISODIUM CITRATE DIHYDRATE | INTRAVENOUS | LIQUID | 0.36 %w/v | Deletion | ||
| Q3 2022 | TRISODIUM CITRATE DIHYDRATE | NASAL | AEROSOL, SPRAY | 17.00 mg | Deletion | ||
| Q2 2022 | TALC | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 20.35 mg | MDE Replacement | ||
| Q3 2022 | TALC | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 20mg | MDE Replacement | ||
| Q2 2022 | TITANIUM DIOXIDE | BUCCAL | FILM | 1.66 mg | MDE Replacement | ||
| Q3 2022 | TITANIUM DIOXIDE | BUCCAL | FILM | 3mg | MDE Replacement | ||
| Q2 2022 | TITANIUM DIOXIDE | ORAL | CAPSULE | 74.20 mg | MDE Replacement | ||
| Q3 2022 | TITANIUM DIOXIDE | ORAL | CAPSULE | 4mg | MDE Replacement | ||
| Q2 2022 | TRIETHYL CITRATE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 7.09 mg | MDE Replacement | ||
| Q3 2022 | TRIETHYL CITRATE | ORAL | CAPSULE, COATED, EXTENDED RELEASE | 7mg | MDE Replacement | ||
| Q2 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (35/65 W/W; 50000000 PA.S) | TRANSDERMAL | SYSTEM | 44.51 mg | MDE Replacement | ||
| Q3 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (35/65 W/W; 50000000 PA.S) | TRANSDERMAL | SYSTEM | 45mg | MDE Replacement | ||
| Q2 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (45/55 W/W; 100000 PA.S) | TRANSDERMAL | FILM, EXTENDED RELEASE | 228.23 mg | MDE Replacement | ||
| Q3 2022 | TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (45/55 W/W; 100000 PA.S) | TRANSDERMAL | FILM, EXTENDED RELEASE | 704mg | MDE Replacement | ||
| Q2 2022 | TRISODIUM CITRATE DIHYDRATE | TOPICAL | CLOTH | 1.68 mg | MDE Replacement | ||
| Q3 2022 | TRISODIUM CITRATE DIHYDRATE | TOPICAL | CLOTH | 2mg | MDE Replacement | ||
| Q2 2022 | TROLAMINE | TOPICAL | CREAM, AUGMENTED | 1.00 %w/w | MDE Replacement | ||
| Q3 2022 | TROLAMINE | TOPICAL | CREAM, AUGMENTED | 20mg | MDE Replacement | ||
| Q2 2022 | TROMETHAMINE | INTRAVENOUS | INJECTION, SOLUTION | 1.21 %w/v | MDE Replacement | ||
| Q3 2022 | TROMETHAMINE | INTRAVENOUS | INJECTION, SOLUTION | 300mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022